Kidney transplantation is often complicated by worsening or new-onset diabetes. The safety and effectiveness of drugs used to lower glucose in this setting is largely unknown. We included ten studies ...

Diabetes is the commonest cause of chronic kidney disease (CKD). Due to decreased kidney function and changes in the clearance of medications and glucose, treating people with diabetes and CKD is ...

Diabetic patients who take anti-diabetic drugs - known as glitazones - long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new ...

Diabetic patients who take anti-diabetic drugs - known as glitazones – long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new ...

More than 12,000 people are diagnosed with brain tumours each year. Survival rates for the cancer are hard to predict but the NHS reports around 17 out of every 100 people with a cancerous brain ...

Diabetic patients who take anti-diabetic drugs - known as glitazones – long term had a lower risk of primary and secondary brain cancer compared with diabetic patients on other medications, new ...

These drugs may successfully prevent dementia in high-risk individuals with mild or moderate type 2 diabetes. According to the scientists, it could be worthwhile to prioritize these drugs for future ...

Use of an older class of type 2 diabetes drugs called glitazones, also known as thiazolidinediones or TZDs for short, is linked to a 22% reduced risk of dementia, reveals a long term study published ...

Glitazones also known as thiazolidinediones or TZDs are older class of type 2 diabetes drugs used for controlling blood sugar effectively. Type 2 diabetes and dementia share some of the same ...

Use of an older class of type 2 diabetes drugs called glitazones, also known as thiazolidinediones or TZDs for short, is linked to a 22% reduced risk of dementia, according to a long-term ...